skip to main content
UK Health Security Agency

KARPAS-422

KARPAS-422

Catalogue No.

06101702

Cell Line Name

KARPAS-422

Cell Line Description

Established from a pleural effusion of 73 year-old woman diagnosed with B-cell non-Hodgkin lymphoma (intra-abdominal, diffuse large cell lymphoma, refractory, terminal). Carries t(14;18) IGH-BCL2 fusion gene (break point in major breakpoint region, MBR).

Access Cell line profile for this product

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Tissue of Origin

Not specified

Morphology

Round polygonal cells growing singly or in small clusters in suspension

Karyotype

Hyperdiploid with 10% polyploidy

Disease

Non-Hodgkin Lymphoma

Culture Conditions

Cell Type

Lymphoblastoid

Subculture Routine

If starting from a frozen ampoule the cryoprotectant should be removed. Add thawed cells to a conical based centrifuge tube e.g. 15ml tube; slowly add 4 ml of culture medium to the tube. Take a sample of the cell suspension, e.g. 100µl, to count cells. Centrifuge the cell suspension at low speed i.e. 100 - 150 x g for a maximum of 5 minutes. Remove medium and resuspend the cell pellet at a density of 5 x 100,000 cells/ml in fresh medium containing 20% serum. Incubate flask at 37°C; 5 - 7% CO₂. Check daily. Keep flask in a vertical position until the cells reach the exponential phase of growth. This can take up to 7 days. Once the culture is established the serum concentration can be reduced to 10%.Maintain cultures between 5 - 20 x100,000 cells/ml by splitting saturated cultures 1:2 every 2-4 days; 5% CO₂; 37°C. Doubling time approximately 60-90 hours. Round polygonal cells growing singly or in small clusters in suspension.

Culture Medium

RPMI 1640 + 2mM Glutamine + 20% Foetal Bovine Serum (FBS).

Growth Mode

Suspension

Additional Info

Depositor

Dr Abraham Karpas, Department of Haematology, University of Cambridge, MRC Centre, Hills Road, Cambridge, UK

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Dyer et al., (1990) A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood 75: 709-14

Bibliography

Not Available

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: KARPAS-422 (ECACC 06101702).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.